Vitamin D3 24-hydroxylase mRNA expression in the skin of calcipotriol-treated psoriatic patients correlates with clinical efficacy

Autor: Stephen Molloy, Jesús Medina, Anne de Brugerolle de Fraissinette, Olivier Grenet, Nicole Hartmann, Valerie Picarles, Salah-Dine Chibout, André Cordier
Rok vydání: 2003
Předmět:
Zdroj: Archives of Dermatological Research. 295:269-271
ISSN: 1432-069X
0340-3696
DOI: 10.1007/s00403-003-0428-1
Popis: calcipotriol, binds to the nu-clear vitamin D receptor and acts as a transcription factor.The result is inhibition of keratinocyte proliferation andpromotion of cell differentiation [2, 3]. New compoundsacting on this pathway, with improved pharmacologicaland safety profiles, are at present being developed [4].Easily measurable, mechanistically based parametersthat, when monitored in vitro, in laboratory animals or inthe clinic, can predict the efficacy of drugs represent use-ful tools for both the researcher and the physician. In thecase of prodrug vitamin D analogues, quantification of thelevels of the active form of calcitriol would theoreticallybe the most suitable indicator of the efficacy of the drugs.However, the determination of calcitriol in tissue extractsor in serum is hampered by the low sensitivity or com-plexity of available techniques (i.e. radioimmunoassays,HPLC or mass spectrometry). For calcipotriol and othervitamin D analogues, no molecular markers of therapeuticefficacy have been identified. Therefore, in most cases,the most reliable alternative for researchers is to performclinical trials and assess the clinical efficacy based on vi-sual scoring of the skin lesions in psoriatic patients.Metabolism of vitamin D (but not of all its analogues[5]) occurs through the C-24 oxidation pathway whosemajor function is to convert 1,25-dihydroxy vitamin D
Databáze: OpenAIRE
Externí odkaz: